Weiqiang Lu Selected Research

Weiqiang Lu Research Topics

Disease

25	Neoplasms (Cancer) 10/2022 - 04/2011
4	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2012
3	Neoplasm Metastasis (Metastasis) 02/2022 - 11/2014
3	Carcinoma (Carcinomatosis) 01/2022 - 07/2016
3	Carcinogenesis 01/2021 - 01/2017
3	Inflammation (Inflammations) 01/2021 - 04/2011
3	Lung Neoplasms (Lung Cancer) 01/2018 - 01/2016
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 01/2015
3	Malaria 04/2014 - 01/2009
2	Pancreatic Neoplasms (Pancreatic Cancer) 02/2022 - 10/2019
2	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2016
2	Triple Negative Breast Neoplasms 01/2021 - 01/2019
2	Systemic Scleroderma (Systemic Sclerosis) 01/2021 - 02/2020
2	Fibrosis (Cirrhosis) 01/2021 - 02/2020
2	Lymphatic Metastasis 08/2018 - 02/2017
2	Drug-Related Side Effects and Adverse Reactions 01/2018 - 12/2016
2	Leukemia 01/2018 - 01/2016
2	Acute Lung Injury 01/2017 - 01/2016
1	Disease Progression 03/2022
1	Pain (Aches) 03/2022
1	Osteoarthritis 03/2022
1	Osteophyte 03/2022
1	Colitis 01/2022
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 11/2021
1	Neuroinflammatory Diseases 01/2021
1	Alzheimer Disease (Alzheimer's Disease) 01/2021
1	Melanoma (Melanoma, Malignant) 10/2020
1	Multiple Sclerosis 01/2020
1	Autoimmune Diseases (Autoimmune Disease) 01/2020
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2020
1	Chronic Pain 11/2019
1	Hyperalgesia 11/2019
1	Adenocarcinoma of Lung 01/2019
1	Cardiac Arrhythmias (Arrythmia) 01/2019
1	Heart Failure 01/2019
1	Type 2 Diabetes Mellitus (MODY) 10/2018

Drug/Important Bio-Agent (IBA)

9	Pharmaceutical PreparationsIBA 02/2022 - 08/2013
5	Biological ProductsIBA 10/2020 - 05/2011
4	Proteins (Proteins, Gene)FDA Link 02/2022 - 01/2016
4	Dihydroorotate DehydrogenaseIBA 01/2022 - 01/2018
3	Dinoprostone (PGE2)FDA Link 03/2022 - 01/2022
2	ProstaglandinsIBA 01/2022 - 01/2020
2	celastrolIBA 01/2021 - 02/2020
2	Bleomycin (Blenoxane)FDA LinkGeneric 01/2021 - 02/2020
2	Therapeutic UsesIBA 01/2020 - 01/2020
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 07/2016
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 10/2017
2	Tyrosine Kinase InhibitorsIBA 01/2018 - 10/2017
2	Leukotriene B4IBA 01/2017 - 01/2016
2	Cisplatin (Platino)FDA LinkGeneric 07/2016 - 01/2015
2	EnzymesIBA 01/2016 - 08/2013
2	Antimalarials (Antimalarial Agents)IBA 04/2014 - 01/2012
1	Interleukin-2 (IL2)IBA 10/2022
1	Adenosine A2 Receptor AntagonistsIBA 10/2022
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 10/2022
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 03/2022
1	Netrin-1IBA 03/2022
1	Gemcitabine FDA Link 02/2022
1	Prostaglandin Receptors (Prostaglandin Receptor)IBA 02/2022
1	Immune Checkpoint ProteinsIBA 01/2022
1	ChemokinesIBA 01/2022
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2022
1	AntibodiesIBA 01/2022
1	Dextran SulfateIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 11/2021
1	Sirtuin 1IBA 01/2021
1	CB2 Cannabinoid ReceptorIBA 01/2021
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2021
1	Estrogen Receptor alphaIBA 01/2021
1	Anti-Allergic Agents (Antiallergic Agents)IBA 01/2021
1	desloratadine (Aerius)FDA LinkGeneric 01/2021
1	Designer DrugsIBA 01/2021
1	pyrimidineIBA 01/2021
1	abemaciclibIBA 01/2021
1	CannabinoidsIBA 01/2021
1	shikoninIBA 01/2021
1	Hormones (Hormone)IBA 01/2021
1	gambogic acidIBA 01/2021
1	corynolineIBA 10/2020
1	Caspase 3 (Caspase-3)IBA 10/2020
1	Cysteine (L-Cysteine)FDA Link 10/2020
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 02/2020
1	indium-bleomycinIBA 02/2020
1	ArrestinIBA 02/2020
1	Topotecan (Hycamtin)FDA LinkGeneric 01/2020
1	piperineIBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Analgesics (Analgesic Drugs)IBA 11/2019
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 11/2019
1	Transient Receptor Potential ChannelsIBA 11/2019
1	triptolideIBA 10/2019
1	Ouabain (G Strophanthin)IBA 01/2019
1	Angiogenesis InhibitorsIBA 01/2019
1	wogonosideIBA 01/2019
1	Nonesterified Fatty Acids (NEFA)IBA 10/2018

Therapy/Procedure

10	Therapeutics 11/2021 - 05/2011
5	Immunotherapy 10/2022 - 01/2020
4	Drug Therapy (Chemotherapy) 02/2022 - 01/2015
3	Oral Administration 01/2022 - 01/2018